
News|Videos|July 28, 2023
Data on Covalent BTK Inhibitors for the Treatment of R/R Mantle Cell Lymphoma
Drs Kami Maddocks and Alexey Danilov review data from ongoing studies evaluating covalent BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5



































